



## **Rapid/STAT Testing Requisition Form**

Please complete every field and tick box clearly.

PATIENT INFORMATION			PATIENT SAMPLE INFORMATION		
PATIENT INFORMATION			SAMPLE TYPE:		
		MM/ DD /YYYY	○ Saliva Swab* ○ Dried Blood Spots		
Patient's First Name	Middle Initial	Patient's Date of Birth	○ Whole Blood* ○ Other		
			* Optional cCMV and StepOne enhancements require DBS		
Patient's Last Name	Patient ID/MR N	lumher	Collection Date: MM/DD/YY YY Was this sample collected in NY State: Oyes Ono		
			INDICATION FOR TESTING (Required)		
Biological Sex: O Male O Female O Gender Identity (if different from above):			ICD10 Code(s):		
Gender Identity (if different from above).			Clinical Diagnosis:		
			Age at Initial Presentation:		
Patient's Street Address			TEST MENU		
			OSTAT Curated Panel by clinical indication		
City / Toylor	toto Zin C	¹ada	Test code: F		
City / Town S	tate Zip C	oue	Test name:		
			○D3000S STAT AnyPanel™ Test		
Country Patier	t's Preferred Phone		Custom exome-based panel (with reflex options). Gene total may range from 2 to		
			1,000 genes; if larger, whole exome sequencing is more efficient. Please submit custom requested gene list for testing at <a href="mailto:apps.perkinelmergenomics.com/genelist">apps.perkinelmergenomics.com/genelist</a> ,		
Patient's Email			and include custom panel ID below.		
Ethnicity (sheek all that apply)	frican American	sian (China, Japan, Korea)	PROVIDE CUSTOM PANEL ID HERE:		
3 ( 113)					
OCaucasian/N. European/S. Europea	n OFinnish	OFrench Canadian	Rapid Whole Exome Sequencing Testing Options  O D1010 Rapid Whole Exome Sequencing Proband Only		
OHispanic OJewish - Ashkenazi	OJewish - Sephardio	○Mediterranean	O D1330F Rapid Whole Exome Sequencing DUO		
OMiddle Eastern			O D1310 Rapid Whole Exome Sequencing TRIO		
(Saudi Arabia, Qatar, Iraq, Turkey)	ONative American	○E. Indian	O D1340F Rapid Whole Exome Sequencing QUAD		
OSoutheast Asian (Vietnam, Cambodia,	Thailand) OSouth	Asian (India, Pakistan)	Ultrarapid Whole Genome Sequencing Testing Options		
0.00	,		O D2010 Ultrarapid Whole Genome Sequencing Proband Only		
Other (specify)			O D2330F Ultrarapid Whole Genome Sequencing DUO		
ORDERING PROVIDER			O D2310 Ultrarapid Whole Genome Sequencing TRIO		
			D2340F Ultrarapid Whole Genome Sequencing QUAD     D0055 Analysis of Secondary Findings*		
			*Not included in cost of ultrarapid testing options		
Provider's First and Last Name			Ultrarapid Whole Genome Sequencing, Proband Optional Enhancements		
			Add these enhancements to any Ultrarapid WGS order for <u>proband only</u> .		
PKIG Ordering Provider Account Numl	per NPI		Checking these boxes will add these services to your order without additional costs to		
			the patient.  Not checking these boxes means that these services will not be included in the order.		
Clinic/Hospital/Institution Name			Congenital Cytomegalovirus (cCMV) Screening* – Not valid after 21 days of age. The		
Clinic/Hospital/Institution Name			most common long-term health problem in babies born with congenital CMV infection is		
			hearing loss, which may be detected soon after birth or later in childhood.		
Provider's Email	Provider's Pr	none	○ StepOne® Newborn Screening Panel* – The StepOne Comprehensive		
			Biochemical Profile is a newborn screening test that can detect more than 70		
Provider's Street Address			disorders in newborns from just a few drops of blood. The analyses conducted by PerkinElmer Genomics produce results that can be used by qualified physicians		
			in the diagnosis of disorders. Evidence of these conditions can be detected in		
	7: 6	V. J.	most affected individuals; however, due to genetic variability, age of patient at		
City / Town	tate Zip C	ode	time of specimen collection, quality of specimen, health status of the patient, and		
			other variables, such conditions may not be detected in all affected patients. Adult reference ranges are unavailable. For information on DNA carrier testing for children		
Country Provide	der's Fax		over 90 days of age, please call 866.463.6436.		
SEND ADDITIONAL COPY OF RESU	LTS TO (If applicable)		Metagenomic Clinical Research Report – The patient consents to participate		
			in a metagenomic screening clinical research study conducted by PerkinElmer		
			Genomics. In this study, whole genome sequencing data will be used to screen		
Name			for pathogenic microorganisms in the patient's sample (at the time of specimen collection) to assist in unbiased culture-independent detection. A research-use-		
			only report will be provided with screening results on potentially disease-causing		
PKIG Ordering Provider Account Number	per Phone Numb	er	microbes in the patient's sample.		
			IRB: 1281574		
Email Address	Fax Number		* These add-ons are only available with the submission of a DBS sample. They cannot be done with Saliva or Whole Blood.		
PHYSICIAN CONFIRMATION OF INFO					
			professional authorized to order genetic testing and confirms that the patient has given ts and limitations. I confirm that testing is medically necessary and that test results may		

impact medical management for the patient. Furthermore, all information on this TRF is true to the best of my knowledge. My signature applies to the informed consent and/or attached letter of medical necessity.

Date

Signature\_





# **Rapid/STAT Testing Requisition Form**

* Please fill out family member section below. Additional samples MUS	T be recei	ved within	3 weeks.		
FAMILIAL INFORMATION (Required with all DUO, TRIO, and QUAD ord	ers)				
FAMILY MEMBER 1:		FA	MILY MEMBER 2:		
Last name, First name			st name, First name		
Date of Birth: MM/DD/YYYY Relation to Proband:  Symptomatic (clinically affected)? Oyes Ono			te of Birth: Relation to Probance mptomatic (clinically affected)?  yes  no	l:	
Sample: OIncluded - Collection Date MM/DD/YY OTo be sent I	ater		mple: OIncluded - Collection Date MM/DD/	○ To be ser	nt later
Cample. Cinducta Condition Date	4101			_ 0.00000.	it late.
FAMILY MEMBER 3:					
			sting, and the associated turn-around time, is in		
Last name, First name		up	on receipt of the proband and all respective fan	illy member sar	npies.
Date of Birth: MM/DD/YYYY Relation to Proband:					
Symptomatic (clinically affected)? Oyes Ono Sample: OIncluded - Collection Date MM/DD/YY OTo be sent I	ater				
Cample. Cinduded Concentration Later Concentration	atoi				
■ INSTITUTIONAL BILLING					
			]		
Institution/Organization Name			PerkinElmer Genomics Billing Account ID		
			] [		
Contact Name			Contact Phone		
			Contact Front		
■ PATIENT (SELF) PAYMENT	-4 -4 41		Test and a selected Test and test be a self-mared by selling	- 077 475 4400 5	)
By providing payment information, you are authorizing PerkinElmer to process payme is required prior to test initiation. The patient's sample will be placed on hold (for up to	30 days) ur	ntil payment	is secured. If the patient does not provide payment to Per	kinElmer within 30	days, the
test order may be canceled. Please note that failure by the patient to respond in a tim  CHECK: \$ Amount Enclosed (Please make checks payab	•		, , , , ,	receipt of the resul	ts report.
• CREDIT CARD (Please fill out all information):	ic to. i ciki	TILITICI OC	netics, me.,		
MM/YY					
Credit Card Number Card Exp. Da	ate CVV		ardholder Printed Name as Appears on Card	Amount	
			pp.		
Credit Card Billing Street Address		City / Town	1	State	Zip Code
Cardholder Signature			Cardholder Phone		
O CONTACT PATIENT FOR PAYMENT INFORMATION					
Mobile Phone			Home Phone		
Email Address			_		





## **Rapid/STAT Testing Requisition Form**

DETAILED MEDICAL RECORDS, CLINICAL SUMMARY, PICTURES AND FAMILY HISTORY MUST BE ATTACHED FOR ALL CASES.

CLINICAL INFORMATION IS CRUCIAL FOR ACCURATE INTERPRETATION OF RESULTS.

## ADDITIONAL OPTIONAL PHENOTYPE / PATIENT HISTORY SECTION (Check all that apply)

Clinical diagnosis: ICD-10 Codes: Age of manifeRapidion: A. NEUROLOGY B. METABOLISM 2. Skin and integument 3. Endocrine 1. Behavioral abnormality O 1. Abnormal creatine kinase O 2.1 Abnormal skin pigmentation O 3.1 Diabetes mellitus O 1.1 Autism O 2. Decreased plasma carnitine O 2.2 Abnormal hair O 3.2 Hypo / hyperparathyroidism O 1.2 Attention deficit disorder O 3. Hyperalaninemia O 2 3 Abnormal nail O 3.3 Hypo / hyperthyroidism O 1.3 Psychiatric diseases O 4. Hypoglycemia O 2.4 Hyperextensible skin H. REPRODUCTION 2. Brain imaging O 5. Increased CSF lactate O 2.5 Ichthyosis O 1. Abnormal external genitalia F. CARDIOVASCULAR O 2.1 Abnormal myelination O 6. Increased serum pyruvate O 2. Abnormal internal genitalia O 2.2 Abnormal cortical gyration O 7. Ketosis O 1. Angioedema O 3. Hypogonadism O 2.3 Agenesis of corpus callosum O 8. Lactic acidosis O 2. Aortic dilatation O 4. Hypospadias O 9. Organic aciduria O 2.4 Brain atrophy O 3. Arrhythmia O 5. Infertility C. EYE O 2.5 Cerebellar hypoplasia I. ONCOLOGY O 4. Coarctation of aorta O 2.6 Heterotopia O 1. Blepharospasm O 5. Defect of atrial septum O 1. Adenomatous polyposis O 2.7 Holoprosencephaly O 2. Cataract O 6. Defect of ventricular septum O 2. Breast carcinoma O 2.8 Hydrocephalus O 3. Coloboma O 7. Dilated cardiomyopathy O 3. Colorectal carcinoma O 2.9 Leukodystrophy O 4. Glaucoma O 8. Hypertension O 4. Leukemia O 2.10 Lissencephaly O 5. Microphthalmos O 9. Hypertrophic cardiomyopathy O 5. Myelofibrosis 3. Developmental delay O 6. Nystagmus O 10. Hypotension O 6. Neoplasm of the lung O 3.1 Delayed motor development O 7. Ophthalmoplegia O 11. Lymphedema O 7. Neoplasm of the skin O 3.2 Delayed language development O 8. Optic atrophy O 12. Malf. of heart and great vessels O 8. Paraganglioma O 3.3 Developmental regression O 9. Ptosis O 13. Myocardial infarction O 9. Pheochromocytoma J. HEMATOLOGY AND IMMUNOLOGY O 14. Stroke O 3.4 Intellectual disability O 10. Retinitis pigmentosa 4. Movement abnormality O 11. Retinoblastoma O 15. Tetralogy of Fallot O 1. Abnormality of coagulation O 4.1 Ataxia O 12. Strabismus O 16. Vasculitis O 2 Anemia O 4.2 Chorea O 13. Visual impairment O 3. Immunodeficiency G. GASTROINTESTINAL, D. MOUTH, THROAT AND EAR GENITOURINARY, ENDOCRINE O 4.3 Dystonia O 4. Neutropenia 1. Gastrointestinal O 4.4 Parkinsonism O 1. Abnormality of dental color O 5. Pancytopenia O 1.1 Aganglionic megacolon 5. Neuromuscular abnormality O 2. Cleft lip / palate O 6. Abnormal hemoglobin O 5.1 Muscular hypotonia O 3. Conductive hearing impair. O 1.2 Constipation O 7. Splenomegaly O 4. External ear malformation O 1.3 Diarrhea O 5.2 Muscular hypertonia O 8. Thrombocytopenia O 1.4 High hepatic transaminases K. PRENATAL AND DEVELOPMENT O 5.3 Hyperreflexia O 5. Hypodontia O 6. Sensoneural hearing impair. O 1.5 Gastroschisis O 5.4 Spasticity O 1. Dysmorphic facial features 6. Seizures O 1.6 Hepatic failure O 2. Failure to thrive E. SKIN, INTEGUMENT AND **SKELETAL** O 6.1 Febrile seizures O 1.7 Hepatomegaly O 3. Hemihypertrophy 1. Skeletal O 6.2 Focal seizures O 1.8 Obesity O 4. Hydrops fetalis O 1.1 Abnormal limb morphology O 6.3 Generalized seizures O 1.9 Pyloric stenosis O 5. IUGR O 1.2 Abnormal skeletal system 7. Others O 1.10 Vomiting O 6. Oligohydramnios O 1.3 Abnormal vertebral column O 7.1 Craniosynostosis 2. Genitourinary O 7. Overgrowth O 1.4 Joint hypermobility O 7.2 Dementia O 2.1 Abnormal renal morphology O 8. Polyhydramnios O 7.3 Encephalopathy O 1.5 Multiple joint contractures O 2.2 Abnormal urinary system O 9. Premature birth O 1.6 Polydactyly O 7.4 Headache / Migraine O 2.3 Hydronephrosis O 10. Short stature O 1.7 Scoliosis O 7.5 Macrocephaly O 2.4 Renal agenesis O 11. Tall stature O 1.8 Syndactyly O 2.5 Renal cyst O 7.6 Microcephaly O 1.9 Talipes equinovarus O 7.7 Neuropathy O 2.6 Renal tubular dysfunction

OTHER:

O 7.8 Stroke







PerkinElmer Genetics, Inc., ("PerkinElmer") requires a completed Patient's Informed Consent Form (ICF) for testing to be performed. The ICF must be completed by the patient, or a legally authorized representative of the patient (or by the healthcare provider where permitted under applicable law or regulation). For any patient below the age of majority, the ICF must be completed by the patient's legally authorized representative.

The purpose of this ICF is to provide you with a description of the Test ordered, known risks and benefits of the Test, anonymization of personal health information ("PHI"), sample and data retention, research opportunities, and the reporting of secondary findings, if applicable. Given the complexity of the type of the Test, it is recommended that you and/or your child receive genetic counseling by a trained genetics professional before and after the testing is performed.

#### **TEST INFORMATION**

Your healthcare provider ("HCP") has recommended that you, or your child, receive enzymatic, biochemical or molecular genetics clinical testing ("Test") indicated on the submitted Test Requisition Form ("Requisition"). For more information on the reasons your HCP has ordered the Test, and the disorders your HCP is having you tested for, please consult with your HCP. You are free to decide if you want this Test performed or not. Providing a Sample and undergoing the Test is voluntary and you may withdraw your consent without penalty at any time.

Enzyme/Biomarker Test: This type of test measures the presence or absence of enzymes/biomarkers and/or their level of activity in an individual. Only the enzymes/biomarkers identified on the requisition will be tested. Results from this type of Test may indicate the presence of a specific condition or conditions, and follow-up confirmatory testing may be recommended.

Genetic/Genomic Test: This type of Test analyzes one or more segments of your DNA depending on the assay requested. This Test is used to identify what, if any, DNA variant(s) you or your child is carrying which is causing the specific disease or condition you are being tested for. Identifying the mutation may be useful for diagnostic and treatment purposes, and allows at-risk family members to be tested. Only the genes identified on the Requisition will be analyzed. In some cases, we may not be able to determine with certainty which gene is actually causing the disease.

#### **TEST METHOD**

If you consent to the Test, your HCP will take a sample of your and/or your child's blood, saliva, body fluid, tissue or other sample type. Your Sample will be sent to PerkinElmer's laboratories in the United States for the Test; the majority of testing will be performed at our laboratory headquarters in Pittsburgh, PA.

Under some circumstances, including inadequate or poor quality sample, an additional Sample may be required for Tests to be performed.

#### **TEST RESULTS**

Your treating HCP has sole responsibility for all decisions concerning the possible management of your diagnosis and disease; PerkinElmer will not provide a diagnosis. PerkinElmer will report Test results only to your HCP via secure email, a secure internet portal, or fax. Your HCP is responsible for communicating with you regarding the results of the Test and may refer you or your child to a specialist for further clinical evaluation and confirmation of diagnosis, if applicable. Possible results for Genetic/Genomic Tests include:

- 1. Positive: A positive genetic test result may indicate that you are a carrier of, predisposed to, or have the specific disease or condition being tested for. A positive genetic test may limit your access to health insurance or life assurance coverage; for example, a life insurance company might ask you to provide genetic information indicating a disorder if this information is available to you.
- 2. Negative: A negative result indicates that no disease-causing variant was identified in the Test performed. No Test can rule out all genetic diseases or conditions. A negative result does not guarantee that you are free from genetic disorders or other medical conditions.
- 3. Inconclusive/Variant of Uncertain Significance: A variant of uncertain significance (VOUS) result indicates that a DNA change was detected, but it is currently unknown if the variant is associated with a genetic disorder. A VOUS is not the same as a positive result and does not clarify whether there is an increased risk to develop a genetic disorder. The variant could be a benign change or it could be indicative of disease/disease-causing.
- 4. Unexpected Results: In rare instances, this Test may reveal an important genetic change that is not directly related to the reason for ordering this test. This information would be disclosed to your HCP if it potentially impacts medical care, and you have consented to receive this type of result

#### TEST REPORT

Reported disease-causing variants are described as pathogenic variant(s), likely pathogenic variants(s), or variant(s) of uncertain significance in genes interpreted to be responsible for, or potentially contributing to, a disease or condition. In addition, variants in genes not known to be associated with disease but for which there is evidence to suggest an association with disease may also be reported. For testing performed on prenatal samples or for screening of apparently healthy individuals, only variants classified as pathogenic or likely pathogenic will be reported.

When Whole Exome Sequencing (WES) or Whole Genome Sequencing (WGS) tests are ordered by your HCP, you have the option to receive some findings not directly related to the reason for ordering the Test called "Secondary Findings". When Secondary Findings are requested, only Pathogenic or Likely Pathogenic findings will be reported, where applicable. Please read the Secondary Findings sections on page 3 and/or 4 of this consent form for more information, and available reporting options. For prenatal samples, secondary findings for the proband are not available.

#### INFORMATION ABOUT PARENTAL AND FAMILIAL SAMPLES

In some circumstances, it may be helpful for additional family members to undergo testing in order to provide information that can aid in the interpretation of the WES/WGS test results. These Tests could be part of a TRIO Test or as stand-alone targeted testing. PerkinElmer, in consultation with the HCP, will decide if other family members need to be tested. If the HCP recommends testing for additional family members, only the Test performed will be reported. If undergoing a TRIO WES or WGS test, family members will have the option to receive information about secondary findings either as a part of the proband report or as a standalone parental report. A full analysis of the parental samples for secondary findings will only be completed if standalone reports are selected (for an additional charge). If family members elect to receive information about secondary findings either as part of the proband report or as a standalone report, the family member must sign all applicable sections on page 3 and/or 4 of this form.

#### **TEST LIMITATIONS**

Due to current limitations in technology and incomplete knowledge of diseases and genes, some variants may not be detected by the Test ordered. There is a possibility that the Test result that is uninterpretable or of unknown significance may require further testing when more information is gained. In rare circumstances, Test results may be suggestive of a condition different from that which was originally considered for the purpose of consenting to this Test. The Test may also find variants or genes that lead to conditions for which you currently do not have symptoms or may not be related to your current condition.

## **TEST RISKS**

Patients and family members may experience anxiety before, during, and/or after testing. Testing multiple family members may reveal that familial relationships are not biologically what they were assumed to be. For example, the Test may indicate non-paternity (the stated father of an individual is not the biological father) or consanguinity (the parents of an individual are closely related by blood). These biological relationships may need to be reported to the HCP who ordered the test.

Taking a blood or tissue sample from you and/or your child may lead to mild pain, bruising, swelling, redness, and a slight risk of infection. Light-headedness, fainting or nausea may occur if your HCP collects blood or tissue samples. These side-effects are typically brief and transient, but you should contact your HCP if you and/or your child require treatment. Under some circumstances an additional sample may be required for Tests to be performed.

A positive test result may limit your access to health insurance or life assurance coverage; for example, a life insurance company might ask you to provide genetic information indicating a disorder if this information is available to you. Please refer to information on the Genetic Information Nondiscrimination Act (GINA) and applicable local laws for more information.





#### U.S. CLINICAL INFORMED CONSENT FORM

#### CONFIDENTIALITY

You have the right to confidential treatment of the Sample and your PHI. Your HCP will provide PerkinElmer with Personal Health Information ("PHI") such as your name, date of birth, gender and clinical symptoms to help track your sample and report results. To maintain confidentiality, the test results will only be released to the referring health care provider, to the ordering laboratory, to the patient/guardian, to other health care providers involved in your diagnosis and treatment, or as otherwise required by law or regulation. Unless required by law, PerkinElmer will not disclose your PHI to any person or entity except with your written consent.

You and your HCP can control how your Sample and PHI are processed. You have the right to request access to your PHI, request corrections of any errors in recorded PHI, or where PHI may be missing or incomplete ask that it be completed. You also have the right to ask that your PHI be erased, subject to law or regulation. You can contact your HCP for such requests and your HCP will contact PerkinElmer, or you can contact PerkinElmer directly by visiting www.perkinelmergenomics.com. If requests for access, correction, completion, or erasure cannot be fulfilled, you will be informed and provided with the reasons why your requests cannot be fulfilled.

#### SAMPLE AND DATA RETENTION

Pursuant to laboratory best practices, your DNA sample will be retained by PerkinElmer for a minimum of two years and then destroyed. Additionally, your PHI, the data from the Tests (including those performed before any withdrawal of consent) and the related reports will be retained by PerkinElmer indefinitely, unless otherwise noted. In some instances, it may be beneficial to you for PerkinElmer to retain your sample for a longer period of time in order to conduct additional testing, and PerkinElmer will do so with appropriate documentation from you or your HCP.

PerkinElmer is requesting consent to keep you and/or your child's anonymized sample and data indefinitely for ongoing test development, scientific research, and/or other activities. This consent is optional, and the Test will be performed whether or not you provide consent to the following:

- · PerkinElmer will anonymize and retain your Sample indefinitely for internal quality control, test validation, assay development and improvement. By allowing PerkinElmer to retain your Sample, you understand and agree that you give up any property rights you may have in the Sample and are donating it to PerkinElmer Genetics, Inc. If you withdraw your consent to use of your anonymized sample, no further anonymization will be performed.
  - 🖵 Check here if you would like to opt out of anonymized sample retention (NY State residents, please see section below). Note, if not checked, this is interpreted as "consent given"
- · PerkinElmer will anonymize your data and retain the anonymized data and related anonymized reports from your Tests indefinitely for statistical and quality analysis, research, scientific and technical development, and market research. PerkinElmer may also share your anonymized data and anonymized report with third parties.
  - 🖵 Check here if you would like to opt out of anonymized data retention. Note, if not checked, this is interpreted as "consent given"

REQUIRED FOR SAMPLES	S COLLECTED IN NEW YORK STATE OF	NLY
----------------------	----------------------------------	-----

No tests other than those authorized shall be performed on the biological sample submitted for testing, and any material derived from the sample (i.e., DNA); this includes testing for internal research and/or quality control purposes. The sample shall be destroyed no more than 60 days after the sample was taken or at the end of the testing process, whichever occurs later, unless indicated below.

☐ By checking here and signing at right, I consent to PerkinElmer keeping my sample for longer than 60 days, and to using my de-identified	
sample for internal research and/or quality control purposes. Note, if not checked and signed, this is interpreted as "consent not given."	Patient/Guardian Signature

#### **RESEARCH OPTIONS**

PerkinElmer may collaborate with scientists, researchers and drug developers to advance knowledge of genetic diseases. If there are opportunities to participate in future research relevant to the disease in you and/or your child, PerkinElmer may contact you or your HCP about the development of new testing, drug development, or other treatments. PerkinElmer may also work with scientists or researchers from academic or commercial institutions who have received the necessary approvals to conduct a research study. In some instances, these scientists or researchers may like to contact you directly about your interest in participating in a specific research study. By checking here I would like to opt out of PerkinElmer being able to provide my contact information to outside researchers to contact me directly about

applicable research studies.

#### WITHDRAWAL OF CONSENT

I understand this consent is voluntary and is valid until I withdraw my consent. I understand I may withdraw my consent to sample and data retention, and to the Test at any time, that PerkinElmer will not perform the Test unless I provide consent to the Test. If I withdraw any consent, it will not affect actions taken before I withdrew my consent, including any anonymization of data or of my Sample. I understand that if I wish to withdraw my consent I should contact PerkinElmer via email at: Genomics@perkinelmer.com or toll-free

by telephone +1-866-354-2910 to request withdrawal.		•		
PATIENT CONSENT TO TESTING				
☐ By checking this box I attest:				
I have read and understood the Informed Consent Form in its entirety risks associated with genetic testing. I have had the opportunity to asl this ICF. My signature below acknowledges my free consent to the Tehealth of an unborn child, or the health of other family members.	, k my ⊦	ICP questions about the information conta	ained herein, and understand that I am entitled to a copy of	
Patient Signature (or Parent/Guardian if patient is minor)		Date		
Patient Name		Name and Relationship	(Parent/Guardian if patient is minor)	
FAMILY MEMBER CONSENT TO TESTING (if applicable)				
□ By checking this box I attest: I have read and understood the Informed Consent Form in its entirety, including the explanation of why my sample is being tested, how genetic testing is performed and the risks associated with genetic testing. I have had the opportunity to ask my HCP questions about the information contained herein, and understand that I am entitled to a copy of this ICF. My signature below acknowledges my free consent to the Test, and to any additional consents indicated above, and such testing in no way guarantees my health, the health of an unborn child, or the health of other family members.				
Family Member Signature	Date	Family Member Name	Relationship to Patient	
FAMILY MEMBER CONSENT TO TESTING (if applicable)				

By checking this box I attest: I have read and understood the Informed Consent Form in its entirety, including the explanation of why my sample is being tested, how genetic testing is performed and the risks associated with genetic testing. I have had the opportunity to ask my HCP questions about the information contained herein, and understand that I am entitled to a copy of this ICF. My signature below acknowledges my free consent to the Test, and to any additional consents indicated above, and such testing in no way guarantees my health, the health of an unborn child, or the health of other family members.

Date Family Member Name Family Member Signature Relationship to Patient





PATIENT SECONDARY FINDINGS CONSENT

### U.S. CLINICAL INFORMED CONSENT FORM

Secondary findings will not be reported with Ultrarapid Whole Genome Sequencing unless test code D0055 is ordered.

## ACMG RECOMMENDED SECONDARY FINDINGS: REQUIRED ONLY FOR WES/WGS

Since many different genes and conditions are being analyzed during the genetic Test, some findings not directly related to the reason for ordering the Test may be revealed. These findings are called "secondary" and can provide information that was not anticipated when the Test was ordered. Secondary findings are variants found in genes that are unrelated to the individual's reported clinical features. One such group of secondary findings available to individuals undergoing WES or WGS are diagnostic findings in genes defined as highly penetrant and medically actionable by the American College of Medical Genetics and Genomics. Please see below for additional information.

The American College of Medical Genetics and Genomics (ACMG), has recommended that secondary findings should be offered for a specific subset of highly penetrant and medically actionable genes associated with various inherited disorders for all individuals undergoing WGS or WES. Please refer to the latest version of the ACMG Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing for complete details of genes and conditions at www.acmg.net. Medically-actionable conditions are those for which there is currently recommended treatment or preventative actions that can be taken to reduce the risk of developing the disease. An example would be hereditary cancer syndromes such as Lynch syndrome.

We are unable to guarantee that the Test will find all medically-actionable conditions for which you have a pathogenic or likely pathogenic variant. You may have a pathogenic or likely pathogenic variant for a condition in which there was little or no coverage in the Test and therefore will not be detected. Additional testing for health purposes should be discussed with your doctor or genetic counselor.

Secondary findings will only be reported if consent is given by the Patient or Parent/Guardian. Each individual receiving secondary findings will need to fill out the appropriate section(s) below to indicate which secondary findings that they will receive. If a box is not checked or this form is not returned, it is assumed that the applicable individual does not want to receive the corresponding secondary finding(s).

Not available for prenatal samples.	OONOLNI		
☐ Check this box if you wish to receive of Medical Genetics and Genomics.	a report on pathogenic or likely pa	athogenic findings in g	enes defined as highly penetrant and medically actionable by the American College
If ACMG recommended Secondary PMID:27854360. The lack of selecti	Findings are elected above, please on will result in return of ALL results	choose if you would li s ("both"). Please note,	ke only pediatric findings, only adult findings, or both as defined by Table 1 in it is recommended that the patient be 18 years or older for the return of adult findings.
Pediatric Findings Only	☐ Adult Findings Only	Both Pedia	tric and Adult Findings
☐ Check this box if you do NOT want to re	ceive ACMG-recommended second	ary findings.	
Patient Signature (or Parent/Guardian if	patient is minor)	D	ate
Patient Name		N	ame and Relationship (Parent/Guardian if patient is minor)
<ul> <li>Return of Secondary Findings re be commented on. This option is</li> <li>Return of findings as a standalor</li> </ul>	f family members included as part of sults as part of the proband report not available for prenatal reports.	will include only the p	ceive secondary findings either as part of a proband report or as a standalone report. arental inheritance of those findings reported in the proband. No other findings will dary Finding sections for each family member. A standalone family member report D this section is filled out entirely.
☐ Check this box if you wish to receive of Medical Genetics and Genomics.	a report on pathogenic or likely pa	athogenic findings in g	enes defined as highly penetrant and medically actionable by the American College
PMID:27854360. The lack of select	ion will result in return of ALL result	s ("both"). Please note	ke only pediatric findings, only adult findings, or both as defined by Table 1 in it is recommended that the patient be 18 years or older for the return of adult findings.
☐ Pediatric Findings Only	☐ Adult Findings Only		tric and Adult Findings
☐ Check this box if you do NOT want to re	ceive ACMG-recommended second	ary findings.	
		=	
Family Member Signature		D	ate
Family Member Name		R	elationship to Patient
<ul> <li>Return of Secondary Findings re be commented on. This option is</li> <li>Return of findings as a standalor</li> </ul>	f family members included as part o sults as part of the proband report not available for prenatal reports.	will include only the p of all selected Second	ceive secondary findings either as part of a proband report or as a standalone report. arental inheritance of those findings reported in the proband. No other findings will dary Finding sections for each family member. A standalone family member report D this section is filled out entirely.
☐ Check this box if you wish to receive of Medical Genetics and Genomics.	a report on pathogenic or likely pa	athogenic findings in g	enes defined as highly penetrant and medically actionable by the American College
			se only pediatric findings, only adult findings, or both as defined by Table 1 in it is recommended that the patient be 18 years or older for the return of adult findings.
Pediatric Findings Only	☐ Adult Findings Only	Both Pedia	tric and Adult Findings
☐ Check this box if you do NOT want to re	ceive ACMG-recommended second	ary findings.	
Family Member Signature		D	ate
Family Member Name		R	elationship to Patient





### U.S. CLINICAL INFORMED CONSENT FORM

Secondary findings will not be reported with Ultrarapid Whole Genome Sequencing unless test code D0055 is ordered.

#### SUPPLEMENTAL SECONDARY FINDINGS OPTIONS: REQUIRED ONLY FOR WES/WGS

Since many different genes and conditions are being analyzed during the genetic Test, some findings not directly related to the reason for ordering the Test may be revealed. These findings are called "secondary" and can provide information that was not anticipated when the Test was ordered. Secondary findings are variants found in genes that are unrelated to the individual's reported clinical features. In addition diagnostic findings in genes defined as highly penetrant and medically actionable by the American College of Medical Genetics and Genomics, PerkinElmer also offers individuals the ability to receive Secondary Findings from three additional categories as defined below:

- 1. Pharmacogenetic variants: This category of Secondary Findings will include changes in the DNA that do not cause a disease but may be related to how your body processes certain medications, such as chemotherapy drugs, antipyretics, antidepressants, anticoagulants, and others. These variants may not be important to you if you are not taking the medications involved, but may tell you how well the medications will work or if you will have side effects if you do take the medications now or in the future.
- 2. Carrier status (ex. cystic fibrosis): This category of Secondary Findings will include carrier findings for autosomal recessive conditions. A recessive condition is one in which two disease-causing variants in the same gene are required in order to show symptoms of the disease (one variant is inherited from each parent). Someone who has only one disease-causing variant does not show symptoms and is called a carrier. However, if we find a disease-causing variant in a recessive gene that is related to your disease, we will report it as a diagnostic finding. Please note that only Pathogenic or Likely Pathogenic variants will be reported if this category of Secondary Findings is selected. Further testing may be necessary to look for a second disease-causing variant in that gene not identified by WES/WGS. The Test is not designed to be a comprehensive carrier test. We are unable to guarantee that all conditions for which you are a carrier will be determined by the Test. You may be a carrier for a condition in which there was little or no coverage in the Testing and therefore will not be detected. Additional carrier testing for reproductive purposes should be discussed with your doctor or genetic counselor.
- 3. Diagnostic findings in all other disease-causing genes not related to your clinical features: This category of Secondary Findings will include conditions that are medically-actionable but not included in the ACMG-recommended list, as well as conditions that are not medically-actionable (do not have recommended treatment or preventative measures), which may be childhood or adult onset. An example would be Alzheimer's disease. Please note that only Pathogenic or Likely Pathogenic variants will be reported if this category of Secondary Findings is selected. Furthermore, we are unable to guarantee that the Test will find all disease-causing variants in all disease-causing genes. You may have a disease-causing variant for a condition in which there was little or no coverage in the Test and therefore will not be detected. Additional testing for health purposes should be discussed with your doctor or genetic counselor.

Secondary findings will only be reported if consent is given by the Patient or Parent/Guardian. Each individual receiving secondary findings will need to fill out the appropriate section(s) below to indicate which secondary findings that they will receive. If a box is not checked or this form is not returned, it is assumed that the applicable individual does not want to receive the corresponding secondary finding(s).

PATIENT SECONDARY FINDINGS CONSENT Not available for prenatal samples.				
If you selected to receive Secondary Findings from category #3 ab	ee category #2 above for details).  ely pathogenic findings in all other disease-causing genes (see category #3 above for details).  bove, please choose if you would like only pediatric findings, only adult findings, or both. The lack of selection mended that the patient be 18 years or older for the return of adult findings.  Both Pediatric and Adult Findings			
Patient Signature (or Parent/Guardian if patient is minor)	Date			
Patient Name	Name and Relationship (Parent/Guardian if patient is minor)			
<ul> <li>Return of Secondary Findings results as part of the proband report be commented on. This option is not available for prenatal report</li> </ul>	sis of all selected Secondary Finding sections for each family member. A standalone family member report			
pharmacogenomic variants will not be included on a proband Check this box if you wish to receive a report on carrier status – (se Check this box if you wish to receive a report including pathogenic or like If you selected to receive Secondary Findings from category #3 ab will result in return of ALL results ("both"). Please note, it is recommendated in the commendate of the commendate in the commendate of	y available when a standalone report is ordered for the family member. Parental inheritance of report.  be category #2 above for details).  ely pathogenic findings in all other disease-causing genes (see category #3 above for details).  bove, please choose if you would like only pediatric findings, only adult findings, or both. The lack of selection mended that the patient be 18 years or older for the return of adult findings.  Both Pediatric and Adult Findings			
Family Member Signature	Date			
Family Member Name	Relationship to Patient			
<ul> <li>Return of Secondary Findings results as part of the proband report be commented on. This option is not available for prenatal report</li> </ul>	sis of all selected Secondary Finding sections for each family member. A standalone family member report			
<ul> <li>□ Check this box if you wish to receive a report on pharmacogenetic variants (see category #1 above for details).         This category of secondary findings for family members is only available when a standalone report is ordered for the family member. Parental inheritance of pharmacogenomic variants will not be included on a proband report.     </li> <li>□ Check this box if you wish to receive a report on carrier status – (see category #2 above for details).</li> <li>□ Check this box if you wish to receive a report including pathogenic or likely pathogenic findings in all other disease-causing genes (see category #3 above for details).         If you selected to receive Secondary Findings from category #3 above, please choose if you would like only pediatric findings, only adult findings, or both. The lack of selection will result in return of ALL results ("both"). Please note, it is recommended that the patient be 18 years or older for the return of adult findings.     </li> <li>□ Pediatric Findings Only □ Adult Findings Only □ Both Pediatric and Adult Findings</li> <li>□ Check this box if you do NOT want to receive any of the secondary finding categories discussed on this page.</li> </ul>				
Family Member Signature	Date			

Relationship to Patient